Hospital
Doctors Hospital of Augusta LLC
Doctors Hospital of Augusta LLC was paid $2.22M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 18% of everything it billed.
33Billing provider infoDOCTORS HOSPITAL OF AUGUSTA LLC
AUGUSTA, GA 30909
AUGUSTA, GA 30909
33aNPI1912951963assigned 05/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.22M
24GClaims84,268
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Georgia
Rank by total paid#8 of 34
Median peer was paid$23K
This provider vs. median96×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,465 | $237K | |
| 2019 | 15,049 | $296K | |
| 2020 | 12,312 | $263K | |
| 2021 | 14,206 | $310K | |
| 2022 | 13,973 | $435K | |
| 2023 | 11,528 | $374K | |
| 2024incomplete | 9,735 | $308K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 18% | 4,475 | 3,626 | $400K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 17% | 14,068 | 8,873 | $381K |
| 16020 | 12% | 2,490 | 1,781 | $257K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 4,745 | 3,993 | $255K |
| 97535 | Self-care/home management training, each 15 minutes | 8.3% | 3,685 | 2,695 | $186K |
| 36415 | Collection of venous blood by venipuncture | 6.4% | 1,112 | 976 | $141K |
| 81001 | 3.3% | 3,707 | 3,144 | $74K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.3% | 3,084 | 2,617 | $73K |
| 15002 | 2.4% | 504 | 424 | $54K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 546 | 493 | $37K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 484 | 429 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 963 | 723 | $26K |
79 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,056 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,906 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 552 | $18K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,527 | $17K |
| 97162 | <1% | 841 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 381 | $17K |
| Q4100 | Skin substitute, not otherwise specified | <1% | 1,211 | $15K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,225 | $14K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 94 | $14K |
| 81025 | <1% | 2,351 | $14K | |
| G0378 | Hospital observation service, per hour | <1% | 908 | $13K |
| 15004 | <1% | 207 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,140 | $12K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 344 | $12K |
| 97168 | <1% | 546 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 418 | $9K |
| 83690 | <1% | 1,818 | $8K | |
| 87077 | <1% | 305 | $8K | |
| 85027 | <1% | 6,541 | $8K | |
| 97166 | <1% | 536 | $7K | |
| 0479T | <1% | 130 | $4K | |
| 97165 | <1% | 200 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,709 | $4K |
| 99285 | Emergency room visit (most serious) | <1% | 142 | $3K |
| J3490 | Unclassified drugs | <1% | 1,330 | $3K |
| 84484 | <1% | 921 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 475 | $3K |
| C5273 | Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children | <1% | 38 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 343 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 14 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,065 | $2K |
| 87070 | <1% | 68 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 76 | $1K |
| 97161 | <1% | 79 | $1K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 44 | $984.91 |
| 97164 | <1% | 59 | $875.86 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 51 | $683.00 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 28 | $430.47 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 53 | $325.02 |
| 84703 | <1% | 33 | $261.53 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $250.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 489 | $232.64 |
| 83880 | <1% | 94 | $154.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,049 | $139.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 850 | $120.60 |
| 87186 | <1% | 218 | $90.36 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 126 | $86.27 |
| 86850 | <1% | 179 | $80.10 | |
| 82247 | <1% | 18 | $56.30 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 27 | $53.41 |
| 85610 | <1% | 875 | $47.81 | |
| 86900 | <1% | 185 | $34.87 | |
| 85730 | <1% | 762 | $31.27 | |
| 86901 | <1% | 185 | $25.23 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,330 | $15.26 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,290 | $8.23 |
| 87205 | 0% | 48 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 60 | $0.00 |
| 87490 | 0% | 14 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 436 | $0.00 |
| 82550 | 0% | 36 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 399 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 51 | $0.00 |
| 83735 | 0% | 109 | $0.00 | |
| 15275 | 0% | 73 | $0.00 | |
| A6208 | Contact layer, sterile, more than 48 sq. in., each dressing | 0% | 253 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 14 | $0.00 |
| 87590 | 0% | 14 | $0.00 | |
| 83605 | 0% | 22 | $0.00 | |
| 15271 | 0% | 12 | $0.00 | |
| 96376 | 0% | 19 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 240 | $0.00 |
| 97760 | 0% | 18 | $0.00 | |
| 85007 | 0% | 13 | $0.00 | |
| C5275 | Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area | 0% | 27 | $0.00 |
| 15274 | 0% | 22 | $0.00 | |
| 15273 | 0% | 27 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 13 | $0.00 |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBYRD, JASON (CFO)